Cagrilintide

1. Product Overview

Property

Detail

Product Name

Cagrilintide (Amylin Analog)

Compound Type

Acylated Synthetic Peptide

Grade

Research Grade

Catalog Number

[To be assigned]

CAS Number

[Not specified]

Molecular Formula

[Not specified]

Molecular Weight

[Not specified]

Storage Conditions

Refer to the Certificate of Analysis (CoA). Typically: -20°C for long-term storage.

2. Description and Mechanism of Action

Cagrilintide is an innovative, long-acting, synthetic analog of the naturally occurring human hormone, amylin (also known as Islet Amyloid Polypeptide or IAPP).

A. Chemical Engineering

Unlike native amylin, Cagrilintide has been acylated—a process where a fatty acid chain is chemically attached to the peptide. This structural modification is key to its therapeutic potential, as it confers significantly improved properties:

1. Extended Half-Life: The acylation dramatically increases the compound's resistance to enzymatic degradation by common peptidases.
2. Increased Binding Affinity: The fatty acid moiety often facilitates non-covalent binding to plasma proteins (such as albumin), slowing its clearance from the circulation and resulting in an extended half-life compared to native amylin and earlier analogs like pramlintide.

B. Biological Activity

Cagrilintide functions primarily as a potent agonist of the amylin receptor (AMY).

Mechanism

Description

Location

Satiety Regulation

Interacts with amylin receptors, particularly the CGRP-receptor-like (CALCRL) and RAMP-dependent heterodimers, in the hindbrain. This action suppresses appetite and reduces overall energy intake.

Central Nervous System (CNS), specifically the hypothalamus and brainstem circuits (e.g., area postrema, arcuate nucleus)

Gastric Emptying

Slows the rate at which the stomach empties its contents into the small intestine, contributing to a feeling of fullness.

Gastrointestinal Tract

Glucagon Suppression

May suppress the postprandial secretion of glucagon, helping to stabilize blood glucose levels.

Pancreas (alpha-cells)

3. Research Applications

Cagrilintide is a critical tool for researchers investigating the complex neuroendocrine regulation of metabolic homeostasis.

A. Metabolic Regulation

• Energy Intake and Expenditure: Studies use Cagrilintide to modulate and quantify the effects of amylin signaling on food consumption, body weight, and energy expenditure in various animal models.
• Obesity and Diabetes Models: Evaluation of Cagrilintide's potential as a stand-alone or combination agent for the management of type 2 diabetes and obesity.
• Insulin Sensitivity: Investigation into the indirect effects of appetite suppression and weight loss on systemic insulin sensitivity and glucose tolerance.

B. Neurobiology

• Amylin Receptor Mapping: Used as a selective agonist to map and characterize amylin receptor populations within the CNS, especially in the hypothalamic and brainstem circuits, such as the arcuate nucleus (ARC).
• Signaling Pathways: Researching the downstream signaling cascades (e.g., cAMP production, receptor internalization) activated upon Cagrilintide binding.
• Neurotransmitter Interaction: Study of its interaction with other satiety-regulating neuropeptides and neurotransmitters.

C. Synergy Studies and Co-formulation Research

A significant area of investigation involves the synergistic potential of Cagrilintide when administered in combination with other major metabolic hormones.

Research Area

Focus of Investigation

GLP-1 Receptor Agonists (GLP-1 RA)

Studying the additive or synergistic effects of co-administering Cagrilintide with GLP-1 RAs (e.g., Semaglutide, Liraglutide). The combination targets both GLP-1 and Amylin receptors, leading to enhanced metabolic benefits.

GIP/GLP-1 Agonists

Exploring triple agonism or novel combination therapies involving multiple incretin and amylin pathways.

4. Usage and Handling Information

A. Precautions

FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USE.

• Cagrilintide should only be handled by trained personnel in a laboratory environment with appropriate safety procedures.
• Consult the relevant Safety Data Sheet (SDS) before handling.

B. Preparation and Solubilization

• Solvent: Cagrilintide is typically soluble in sterile water or buffered solutions (e.g., PBS, pH 7.4). The specific solvent may vary based on the intended experiment (e.g., in vitro vs. in vivo).
• Concentration: Prepare stock solutions at a high concentration, aliquot into single-use vials, and freeze to minimize degradation from repeated freeze-thaw cycles.

C. Stability and Storage

• Lyophilized Powder: Store the lyophilized peptide at -20°C or below in a sealed container, protected from light and moisture.
• Reconstituted Solution: Reconstituted solutions should be used immediately. If storage is necessary, aliquot and freeze at -20°C or -80°C for up to [timeframe] to be determined by the researcher, avoiding multiple freeze-thaw cycles.

5. Related Reagents and Resources

• Certificate of Analysis (CoA): Contains batch-specific purity data and quality controls. File
• Safety Data Sheet (SDS): Essential safety and handling information. File
• Technical Support: Contact Person at [email protected] for technical inquiries.
• Place an Order: